Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda)
Diffuse Large B-Cell Lymphoma
Explore 253 assets in Diffuse Large B-Cell Lymphoma →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Sanofi
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
16Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05179603CT.gov A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda) (this asset) | Sanofi | P2 | D · 30 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| (+)-Vincristine | Beth Israel Deaconess Medical Center | P4 | BBB |
| Dexasone | Mwanasha Merrill, MD | P4 | BBB |
| Rituximab | Beth Israel Deaconess Medical Center | P4 | BBB |
| Cyclophosphamide | Beth Israel Deaconess Medical Center | P4 | BBB |
| Etoposide | The First Affiliated Hospital with Nanjing Medical University | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | — | P2 | C · 33 |
| Esophageal Adenocarcinoma | — | P2 | C · 33 |
| Classic Hodgkin Lymphoma | — | P2 | D · 31 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda) in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-interleukin-2-il2-t-cell-growth-factor-tcgf-2-133-variant-a1-deleted-pro65lys-cys125ser-non-glycosylated-produced-in-escherichia-coli-conjugated-at-n6-of-k65-with-a-peg-derivative-30kda-diffuse-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →